Nuvectis Pharma Inc. (NVCT): Price and Financial Metrics
NVCT Price/Volume Stats
| Current price | $13.94 | 52-week high | $18.65 |
| Prev. close | $13.68 | 52-week low | $6.21 |
| Day low | $13.59 | Volume | 25,700 |
| Day high | $14.96 | Avg. volume | 55,080 |
| 50-day MA | $14.40 | Dividend yield | N/A |
| 200-day MA | $12.99 | Market Cap | 240.20M |
NVCT Stock Price Chart Interactive Chart >
Nuvectis Pharma Inc. (NVCT) Company Bio
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
Latest NVCT News From Around the Web
Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AA |
With 67% ownership, insiders at Nuvectis Pharma, Inc. (NASDAQ:NVCT) are pretty optimistic and have been buying recentlyKey Insights Significant insider control over Nuvectis Pharma implies vested interests in company growth The top 4... |
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical TrialFort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”). The study is designed to evaluate the safety, tolerability |
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ETFort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, |
Nuvectis Pharma Announces Participation at Upcoming Investor ConferencesFort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences: Event H.C. Wainwright 25th Annual Global Investment Conference Date |
NVCT Price Returns
| 1-mo | -3.73% |
| 3-mo | -17.76% |
| 6-mo | 16.36% |
| 1-year | 77.13% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 85.87% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...